Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Latest Information Update: 08 May 2025
At a glance
- Drugs T-cell vaccine-TVAX Biomedical (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors TVAX Biomedical
Most Recent Events
- 30 Apr 2025 Status changed from recruiting to suspended due to insufficient funds.
- 16 Jul 2024 Planned number of patients changed from 96 to 120.
- 16 Jul 2024 Planned End Date changed from 1 Mar 2026 to 1 Mar 2027.